Welcome to our dedicated page for Icad news (Ticker: ICAD), a resource for investors and traders seeking the latest updates and insights on Icad stock.
ICAD Inc. (symbol: ICAD) is a leading force in the realm of medical technology, specializing in advanced image analysis, workflow solutions, and radiation therapies designed for the early detection and treatment of cancers.
Core Business: The company’s main operations focus on providing healthcare professionals with cutting-edge tools to identify pathologies through a comprehensive range of high-performance, upgradeable computer-aided detection (CAD) solutions. These solutions are pivotal in mammography for breast cancer, magnetic resonance imaging (MRI) for breast and prostate cancers, and computed tomography (CT) for colorectal cancer. ICAD’s flagship technology, the Xoft® System, delivers radiation treatment for early-stage breast cancer via intraoperative radiation therapy (IORT) and accelerated partial breast irradiation (APBI). Additionally, the Xoft System is approved for treating non-melanoma skin cancer and endometrial cancer.
Recent Achievements and Partnerships: Recently, ICAD announced the integration of key AI-powered solutions from its ProFound™ Breast Health Suite into GE HealthCare's MyBreastAI Suite, aimed at enhancing breast cancer detection worldwide. This collaboration underscores ICAD's commitment to advancing breast health, improving diagnostic accuracy, and streamlining workflow efficiency for clinicians.
Financial Condition: As of the first quarter of 2024, ICAD reported a total revenue of $5.0 million, marking a 14% increase from the previous year. The company's gross profit stood at $4.1 million, with an operating expense reduction of 18%, showcasing robust financial health and strategic cost management.
Global Reach: ICAD’s influence extends across multiple countries including France, Belgium, Italy, Germany, Switzerland, and others, reflecting its strong international presence and commitment to global healthcare improvement.
Innovative Solutions: ICAD’s ProFound AI technology has demonstrated significant benefits in clinical studies, including improved radiologist sensitivity and specificity, reduced reading times, and decreased unnecessary patient recall rates. The company’s solutions are used by thousands of providers, serving millions of patients, and are available in over 50 countries.
Future Prospects: ICAD continues to innovate with the recent introduction of the ProFound Cloud, powered by Google Cloud, to enhance the accessibility and efficiency of mammography screening data. The company also remains committed to expanding its AI capabilities and improving patient outcomes globally through strategic partnerships and technological advancements.
For more information, visit www.icadmed.com or contact their media and investor relations at pr@icadmed.com and ir@icadmed.com respectively.
iCAD (NASDAQ: ICAD) reported strong financial results for Q2 2024. Total revenue increased by 21% to $5.0 million, driven by a 41.4% growth in product revenue. The company's gross profit margin improved to 84% from 81% in Q2 2023. GAAP Net loss from continuing operations decreased to ($1.7) million from ($2.3 million) in the same period last year.
Highlights include:
- Total ARR (Annual Recurring Revenue) reached $9.2 million, up 7% YoY
- 60 perpetual, 29 subscription, and 10 cloud deals closed in Q2
- ProFound Cloud SaaS platform launched successfully
- Cash and cash equivalents stood at $20.4 million as of June 30, 2024
iCAD's strategic focus on maximizing revenue from its install base and transitioning to cloud-based solutions appears to be yielding positive results.
iCAD Inc (NASDAQ: ICAD), a leader in AI-powered cancer detection solutions, has announced its plan to release Q2 2024 financial results on August 13, 2024, after market close. The company will host a conference call at 4:30 PM Eastern Time on the same day to discuss the results. Investors and analysts can access the call via toll-free number 888-506-0062 (US) or 973-528-0011 (International) using the participant access code 227167. A webcast of the earnings call will also be available for those who prefer to listen online.
iCAD (NASDAQ: ICAD) has announced a strategic agreement with Windsong Radiology Group, part of US Radiology Specialists, to implement iCAD's ProFound AI Breast Health Suite at Windsong Radiology centers. This AI-powered technology aims to improve mammography readings' accuracy and efficiency, potentially reducing false positives and unnecessary biopsies.
The collaboration aligns with iCAD's mission to enhance early cancer detection and provide broader access to AI capabilities in mammography. Windsong Radiology, as a leader in women's imaging, views this adoption as a step towards clinical excellence and innovation in patient care. US Radiology Specialists, with over 175 outpatient imaging centers across 13 states, sees this integration as a significant advancement in offering high-quality imaging services.
iCAD announced new research showcasing the ProFound AI Risk algorithm’s efficacy in breast cancer risk prediction. Presented at the Society for Imaging Informatics in Medicine (SIIM) Annual Meeting, the study highlights the AI's ability to identify high-risk individuals by analyzing changes in mammographic features. The research suggests a two-fold increase in risk for every 0.2 unit increase in the AI-derived score.
Additionally, iCAD introduced ProFound Cloud, a SaaS platform built on Google Cloud. This platform provides scalable, secure, and cost-effective access to the company's breast health AI solutions, enhancing diagnostic accuracy and operational efficiency. Preliminary data shows it processes cases 50% faster than traditional methods. Healthcare providers can integrate these solutions to improve patient outcomes while reducing infrastructure costs.
iCAD, a leader in AI-powered breast health solutions, will present at the MedInvest MedTech, AI & Digital Healthcare Conference in San Francisco on June 11-12, 2024. CEO Dana Brown and CFO Eric Lonnqvist will participate in one-on-one meetings with investors. This event underscores iCAD's commitment to leveraging AI in cancer detection and its ongoing engagement with the investment community.
iCAD (NASDAQ: ICAD) reported its financial results for Q1 2024, showing notable improvements across several metrics. Total revenue increased by 14% year-over-year to $5.0 million. Gross profit margin rose to 83% from 82%, contributing to a gross profit of $4.1 million. Despite a GAAP net loss of $1.2 million, this marks a significant improvement from the $3.1 million loss in Q1 2023. Operating expenses decreased by 18% to $5.6 million. The company's ARR also grew by 10% to $9.0 million. Cash and cash equivalents stood at $20.3 million as of March 31, 2024.
iCAD, Inc. (NASDAQ: ICAD) will report its financial results for the first quarter of 2024 on May 15, 2024, and host a conference call at 8:30 AM Eastern Time. The company specializes in AI-powered cancer detection solutions.
iCAD, Inc. will report its first quarter financial results on May 15, 2024. The company specializes in AI-powered cancer detection solutions. The earnings call will provide insights into the company's performance for the quarter ended March 31, 2024.
FAQ
What is the current stock price of Icad (ICAD)?
What is the market cap of Icad (ICAD)?
What does ICAD Inc. specialize in?
What are ICAD's core products?
What recent partnerships has ICAD announced?
How is ICAD performing financially?
Where does ICAD operate globally?
What is the ProFound Cloud?
What are the benefits of ICAD’s ProFound AI technology?
How many patients and providers use ICAD's solutions?
What is the Xoft System?
How can I contact ICAD for more information?
